Rafael (NYSE:RFL) Shares Up 4.6% – Here’s What Happened

Posted by Brian Himes on Aug 21st, 2026

Shares of Rafael Holdings, Inc. (NYSE:RFL – Get Free Report) traded up 4.6% during trading on Thursday . The stock traded as high as $1.94 and last traded at $1.8940. Approximately 79,259 shares traded hands during mid-day trading, a decline of 17% from the average daily volume of 95,924 shares. The stock had previously closed at $1.81.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on RFL. Wall Street Zen upgraded shares of Rafael to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings upgraded shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Get Our Latest Research Report on RFL

Rafael Stock Performance

The business has a 50 day moving average price of $2.36 and a 200-day moving average price of $1.69. The company has a market capitalization of $98.49 million, a price-to-earnings ratio of -2.79 and a beta of 0.33.

Hedge Funds Weigh In On Rafael

A number of institutional investors and hedge funds have recently modified their holdings of RFL. Geode Capital Management LLC boosted its stake in Rafael by 72.9% during the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock worth $781,000 after acquiring an additional 190,179 shares in the last quarter. Kahn Brothers Group Inc. bought a new stake in Rafael in the second quarter valued at $494,000. Vanguard Group Inc. increased its stake in Rafael by 10.5% in the third quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after purchasing an additional 133,024 shares in the last quarter. Cable Car Capital LP acquired a new position in shares of Rafael during the second quarter valued at about $173,000. Finally, Citadel Advisors LLC raised its holdings in shares of Rafael by 132.3% during the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after purchasing an additional 41,335 shares during the period. 11.30% of the stock is currently owned by institutional investors.

Rafael Company Profile

(Get Free Report)

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.